Feb 15, 2023

Featuring perspectives from Drs Jonathan Strosberg and Lori Wirth, including the following topics:

• Nontargeted Treatment for Thyroid Cancer   
  • Introduction (0:00)
  • Case: A woman in her late 60s with poorly differentiated thyroid cancer initially treated with lenvatinib – Dr Wirth (6:05)
• NTRK Fusions in Thyroid Cancer  
  • Case: A woman in her early 60s with metastatic papillary thyroid cancer with an NTRK fusion who received repotrectinib – Eric Sherman, MD (13:27)
  • Case: A man in his early 60s with metastatic papillary thyroid cancer with NTRK fusion who received larotrectinib – Dr Wirth (18:37)
• RET Mutations/Fusions in Thyroid Cancer  
  • Case: A man in his early 40s who presents with metastatic medullary thyroid cancer with a RET mutation – Dr Sherman (21:43)
  • Case: A man in his early 40s with metastatic medullary thyroid cancer with a RET mutation who received selpercatnib – Dr Wirth (27:49)
• Somatostatin Analogs for Neuroendocrine Tumors (NETs) 
  • Case: A woman in her early 50s with a newly well-differentiated small-bowel NET and low-volume liver metastases – Pamela Kunz, MD (33:41)
• Management of Carcinoid Syndrome with NETs  
  • Cases: A man in his early 60s with a well-differentiated small-bowel NET with stable disease on octreotide who is now experiencing increasing diarrhea and a man in his early 60s who received telotristat ethyl for carcinoid syndrome diarrhea – Dr Kunz and Dr Strosberg (41:25)
• Von Hippel-Lindau-Associated Pancreatic NETs  
  • Case: A woman in her late 40s with von Hippel-Lindau syndrome and a pancreatic NET who received belzutifan – Dr Strosberg (49:42)
  • Case: A man in his early 60s with a symptomatic, well-differentiated hypervascular pancreatic NET with bulky liver metastases – Dr Kunz (55:38)

CME information and select publications